The deal values each share at $7.50, with the acquisition to be completed in cash within 60 days, subject to applicable regulatory approvals, including those under the Hart-Scott-Rodino Antitrust Improvements Act and clearance from the Committee for Foreign Investment in the United States (CFIUS). Shares of Zydus Lifesciences Ltd ended at ₹924.30, down by ₹4.65, or 0.50%, on the BSE.
